Webinar: Empty Sella Syndrome
Dr. Manish Aghi
Associate Professor in Residence of Neurological Surgery
Principal Investigator, BTRC
Maydan Family Endowed Faculty
Attending Neurosurgeon, California Center for Pituitary Disorders
Co-Director, Center for Minimally Invasive Skull Base Surgery
Faculty Member, UCSF Graduate Division in Biomedical Sciences
After registering you will receive a confirmation email with details about joining the webinar.
Contact us at email@example.com with any questions or suggestions.
Date: Monday, November 2, 2015
Time: 11:00 AM - 12:00 PM PST
After registering you will receive a confirmation email containing information about joining the Webinar.
When the pituitary gland shrinks or becomes flattened, it cannot be seen on an MRI, making the pituitary gland look like an “empty sella.” The appearance of this term in radiology reports can cause anxiety for patients or confusion for providers who are not familiar with pituitary biology. In this webinar, Dr. Aghi will discuss what tissue can actually be found in a true “empty sella;” what causes an empty sella; and what, if anything, needs to be done about an empty sella.
Dr. Manish Aghi is a neurosurgeon specializing in the treatment of pituitary adenomas and other tumors of the anterior skull base by minimally invasive endonasal approaches. He has an MD and PhD from Harvard Medical School in Boston and did his neurosurgery residency at the Harvard affiliated Massachusetts General Hospital (MGH). Since joining UCSF six years ago, he has performed nearly 500 endonasal operations for pituitary tumors and, as the leader of an active clinical research program, he has published 24 articles on surgical technique and outcomes for pituitary tumor patients. He is currently directing a national effort sponsored by the Congress of Neurological Surgeons to establish evidence-based guidelines for neurosurgeons caring for patients with pituitary tumors.
Dr. Aghi also runs an NIH funded basic science laboratory investigating the molecules that allow pituitary tumors to grow and invade, and he is working with industry collaborators to develop molecular inhibitors that may someday be of benefit to prevent these processes. He is principal investigator of a pair of phase I/II clinical trials of experimental treatments for malignant brain tumors.